EGFR and non-small cell lung carcinoma: Previous research supports the use of EGFR-TKI and chemotherapy combinations in these patients, with studies showing better outcomes with carboplatin-pemetrexed plus gefitinib compared to gefitinib alone in EGFR-mutated advanced NSCLC, including those with baseline CNS metastases (Hosomi et al., 2020; Noronha et al., 2020; Hou et al., 2023).